Cargando…
Lenvatinib Plus Programmed Cell Death Protein-1 Inhibitor Beyond First-Line Systemic Therapy in Refractory Advanced Biliary Tract Cancer: A Real-World Retrospective Study in China
BACKGROUND: Currently, no second-line systemic treatment regimen has been recommended in advanced biliary tract cancer (BTC). Cumulative clinical evidence showed that systemic treatment with tyrosine kinase inhibitors (TKIs) in combination with immunotherapy may shed light on the dim clinical outcom...
Autores principales: | Shi, Changying, Li, Yulong, Yang, Cheng, Qiao, Liang, Tang, Liukang, Zheng, Yuting, Chen, Xue, Qian, Youwen, Yang, Jiamei, Wu, Dong, Xie, Feng |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9364266/ https://www.ncbi.nlm.nih.gov/pubmed/35967452 http://dx.doi.org/10.3389/fimmu.2022.946861 |
Ejemplares similares
-
Lenvatinib Beyond First-Line Therapy in Patients With Advanced Biliary Tract Carcinoma
por: Wang, Yunchao, et al.
Publicado: (2022) -
Efficacy and safety of lenvatinib combined with PD-1/PD-L1 inhibitors plus Gemox chemotherapy in advanced biliary tract cancer
por: Zhu, Chengpei, et al.
Publicado: (2023) -
Effectiveness and safety of lenvatinib plus anti‐programmed death‐1 antibodies in patients with hepatocellular carcinoma: A real‐world cohort study
por: Xu, Ming‐Hao, et al.
Publicado: (2023) -
Real-world efficiency of lenvatinib plus PD-1 blockades in advanced hepatocellular carcinoma: an exploration for expanded indications
por: Sun, Xuqi, et al.
Publicado: (2022) -
Lenvatinib Plus PD-1 Inhibitors as First-Line Treatment in Patients With Unresectable Biliary Tract Cancer: A Single-Arm, Open-Label, Phase II Study
por: Zhang, Qiyi, et al.
Publicado: (2021)